Effect-site Concentration of Remifentanil for Blunting Hemodynamic Responses to Double-lumen Endobronchial Intubation
Information source: Jeju National University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Intubation, Intratracheal
Intervention: Remifentanil (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Jeju National University School of Medicine Overall contact: Hyun Jung Kim, MD, PhD, Phone: 82-64-717-2026, Email: hjanesthesia@empas.com
Summary
The purpose of this study is the comparison of the effect-site concentration of remifentanil
for blunting hemodynamic responses to ordinary tracheal and double-lumen endobronchial
intubation during propofol-remifentanil total intravenous anesthesia.
Clinical Details
Official title: Comparison of the Effect-site Concentration of Remifentanil for Blunting Hemodynamic Responses to Ordinary Tracheal and Double-lumen Endobronchial Intubation During Propofol-remifentanil Total Intravenous Anesthesia
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Primary outcome: arterial blood pressure
Secondary outcome: heart rate
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adult patient who is needed intubation for general anesthesia
Exclusion Criteria:
- patient who is anticipating difficult airway
- patient who takes any drug to influence this study
- cardiovascular disease, renal disease, liver disease
Locations and Contacts
Hyun Jung Kim, MD, PhD, Phone: 82-64-717-2026, Email: hjanesthesia@empas.com
Jeju National University Hospital, Jeju-si, Jeju Special Self-Governing Province 690-767, Korea, Republic of; Recruiting Hyun Jung Kim, MD, PhD, Phone: 82-64-717-2026, Email: hjanesthesia@empas.com
Additional Information
Starting date: October 2013
Last updated: November 27, 2013
|